Saarinen A, Jekunen A, Halme M, Pyrhönen S, Tamminen K, Boyer R, Roubille N, Mattson K
Department of Internal Medicine, Helsinki University Central Hospital, Finland.
Anticancer Drugs. 1996 Nov;7(8):890-2. doi: 10.1097/00001813-199611000-00012.
Twenty-nine patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) were treated with docetaxel. Ten patients had already received chemotherapy, the others had received no chemotherapy. Docetaxel was administrated i.v. over 60 min every 21 days at a dose of 100 mg/m2. Twenty-three patients were evaluable for response. There were no complete responses and eight partial responses. The overall response rate was 35% (28% in the intent to treat analysis). Median duration of response was 43 weeks and median time to progression 12 weeks. Neutropenic infections, neurotoxicity and asthenia were dose-limiting toxicities (6% of 118 cycles). The other main toxicities were asthenia in 48%, skin reactions in 31% and nail changes in 31% of the patients. Single-agent docetaxel appears to be active against both previously treated and untreated advanced NSCLC. Toxicity was acceptable but should be carefully monitored.
29例局部晚期或转移性非小细胞肺癌（NSCLC）患者接受了多西他赛治疗。10例患者此前已接受过化疗，其余患者未接受过化疗。多西他赛通过静脉滴注给药，每21天一次，每次60分钟，剂量为100mg/m²。23例患者可评估疗效。无完全缓解，8例部分缓解。总缓解率为35%（意向性分析中为28%）。中位缓解持续时间为43周，中位疾病进展时间为12周。中性粒细胞减少性感染、神经毒性和乏力为剂量限制性毒性（118个周期中的6%）。其他主要毒性反应为乏力（48%的患者）、皮肤反应（31%的患者）和指甲改变（31%的患者）。单药多西他赛似乎对既往接受过治疗和未接受过治疗的晚期NSCLC均有活性。毒性反应可接受，但应仔细监测。
